Not Yet RecruitingPhase 2

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

323 participantsStarted 2026-05-01

Plain-language summary

The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent must be obtained prior to participation in the study.
✓. Successful completion of treatment period on QCZ484 study medication in parent study.
✓. No significant safety issue that may place participant at safety risk as determined by the Investigator.

Exclusion criteria

✕. Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator.
✕. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study.
✕. Permanent or persistent atrial fibrillation developed during the parent study.
✕. Clinically significant valvular heart disease developed during the parent study.
✕. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment.

What they're measuring

Number of participants with AEs

Timeframe: Up to 66 months

Trial details

NCT IDNCT07543120

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2031-05-31

Contact for this trial

Novartis Pharmaceuticals

1-888-669-6682 novartis.email@novartis.com

View on ClinicalTrials.gov More Hypertension (HTN) trials